Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, Fariduddin M, Vo KT, Ku BJ, Kumar A, Latif ZA, Malek R, Matawaran BJ, Mehta R, Tran NQ, Panelo A, Ruder S, Saldana JR, Shaikh KA, Shakya A, Shrestha D, Unnikrishnan AG. Kalra S, et al. Among authors: vo kt. Adv Ther. 2018 Jul;35(7):937-938. doi: 10.1007/s12325-018-0728-7. Adv Ther. 2018. PMID: 29882121 Free PMC article.
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, Fariduddin M, Vo KT, Ku BJ, Kumar A, Latif ZA, Malek R, Matawaran BJ, Mehta R, Tran NQ, Panelo A, Ruder S, Saldana JR, Shaikh KA, Shakya A, Shrestha D, Unnikrishnan AG. Kalra S, et al. Among authors: vo kt. Adv Ther. 2018 Jul;35(7):928-936. doi: 10.1007/s12325-018-0712-2. Epub 2018 May 23. Adv Ther. 2018. PMID: 29796928 Free PMC article. Review.
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Vo KT, Sabnis AJ, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Jaju A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Vo KT, et al. JCO Precis Oncol. 2024 Jun;8:e2400103. doi: 10.1200/PO.24.00103. JCO Precis Oncol. 2024. PMID: 38935895 Clinical Trial.
Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.
Liu KX, Shaaban SG, Chen JJ, Bagatell R, Lerman BJ, Catalano PJ, DuBois SG, Shusterman S, Ioakeim-Ioannidou M, Yock TI, Shamberger RC, Mattei P, Vu L, Elhalawani H, Dusenbery KE, Vo KT, Huang MS, Friedmann AM, Diller LR, Marcus KJ, MacDonald SM, Terezakis SA, Braunstein SE, Hill-Kayser CE, Haas-Kogan DA. Liu KX, et al. Among authors: vo kt. Radiother Oncol. 2024 Sep;198:110384. doi: 10.1016/j.radonc.2024.110384. Epub 2024 Jun 15. Radiother Oncol. 2024. PMID: 38880415
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma.
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. Batra V, et al. Among authors: vo kt. Pediatr Blood Cancer. 2024 Jan;71(1):e30743. doi: 10.1002/pbc.30743. Epub 2023 Oct 26. Pediatr Blood Cancer. 2024. PMID: 37885116 Free PMC article.
62 results